SNA028
/ SmartNuclide Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 16, 2026
A Preliminary Efficacy of SNA028 in Patients With Advanced Colorectal Cancer Positive for GPA33
(clinicaltrials.gov)
- P1 | N=20 | Not yet recruiting | Sponsor: SmartNuclide Biopharma
First-in-human • New P1 trial • Colorectal Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1